GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » IsoPlexis Corp (NAS:ISO) » Definitions » Net Change in Cash

IsoPlexis (IsoPlexis) Net Change in Cash : $-89.13 Mil (TTM As of Dec. 2022)


View and export this data going back to 2021. Start your Free Trial

What is IsoPlexis Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

IsoPlexis's Net Change in Cash for the three months ended in Dec. 2022 was $-15.69 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2022 was $-89.13 Mil.

IsoPlexis Net Change in Cash Historical Data

The historical data trend for IsoPlexis's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IsoPlexis Net Change in Cash Chart

IsoPlexis Annual Data
Trend Dec19 Dec20 Dec21 Dec22
Net Change in Cash
5.35 79.27 19.93 -89.10

IsoPlexis Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Net Change in Cash Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 85.83 -28.96 -26.00 -18.48 -15.69

IsoPlexis Net Change in Cash Calculation

IsoPlexis's Net Change in Cash for the fiscal year that ended in Dec. 2022 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-96.642+-7.815+15.33+0.026
=-89.10

IsoPlexis's Net Change in Cash for the quarter that ended in Dec. 2022

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-15.478+-0.267+0.056+0
=-15.69

Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-89.13 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

IsoPlexis Net Change in Cash Related Terms

Thank you for viewing the detailed overview of IsoPlexis's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

IsoPlexis (IsoPlexis) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » IsoPlexis Corp (NAS:ISO) » Definitions » Net Change in Cash
Comparable Companies
VAPO AZYO LHDX LUCD SONX EYES CTSO LNSR CFMS PAVM ABT MDT SYK EW BSX SZSE:300760 DXCM ZBH STE ALGN
Traded in Other Exchanges
N/A
Address
35 North East Industrial Road, Branford, CT, USA, 06405
Website
https://www.isoplexis.com
IsoPlexis Corp is a developer of a single-cell detection system designed to accelerate insights in the field of cancer. It designed a platform to reveal functional protein biology and cellular signaling networks at single-cell resolution to accelerate the development of advanced medicines.
Executives
Nachum Shamir director 12212 TECHNOLOGY BLVD, AUSTIN TX 78727
John Strahley officer: Chief Financial Officer 35 NORTH EAST INDUSTRIAL ROAD, BRANFORD CT 06405
Sean Mackay director, officer: Chief Executive Officer 35 NORTH EAST INDUSTRIAL ROAD, BRANFORD CT 06405
Rew Richard W. Ii officer: SVP, GC & Secretary 7000 WEST WILLIAM CANNON, BUILDING ONE, AUSTIN TX 78735
James R Heath director C/O ISOPLEXIS, 35 NE INDUSTRIAL RD, BRANFORD CT 06405
Michael Egholm director 1 FRANKLIN STREET, UNIT 3104, BOSTON MA 02110
Siddhartha Kadia director 7475 LUSK BOULEVARD, SAN DIEGO CA 92121
Jason W. Myers director C/O ARCHERDX, INC., 2477 55TH STREET, SUITE 202, BOULDER CO 80301
John G. Conley director 396 GREAT MEADOWS RD, CONCORD MA 01742-1803
Gregory P. Ho director, 10 percent owner C/O SPRING MOUNTAIN CAPITAL, LP, 650 MADISON AVENUE, 20TH FLOOR, NEW YORK NY 10022
Peter Siesel officer: Chief Commercial Officer 35 NORTH EAST INDUSTRIAL ROAD, BRANFORD CT 06405
Jing Zhou officer: Chief Scientific Officer 35 NORTH EAST INDUSTRIAL ROAD, BRANFORD CT 06405
Rajesh T. Khakhar officer: VP, Finance 35 NORTH INDUSTRIAL ROAD, BRANFORD CT 06405
Northpond Capital Gp, Llc 10 percent owner 4 BRATTLE STREET, FLOOR 3, CAMBRIDGE MA 02138
Perceptive Life Sciences Master Fund Ltd 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003

IsoPlexis (IsoPlexis) Headlines

From GuruFocus

IsoPlexis Strengthens International Reach and Leadership with First APAC Office and Jason Ou as President/General Manager, APAC Region

By GuruFocusNews GuruFocusNews • 02-02-2022

IsoPlexis Reports First Quarter 2022 Financial Results

By GuruFocusNews GuruFocusNews • 05-11-2022

ISOPLEXIS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of IsoPlexis Corporation - ISO

By Business Wire Business Wire • 12-30-2022

IsoPlexis Reports First Quarter 2022 Financial Results

By GuruFocusNews GuruFocusNews • 06-30-2022

IsoPlexis to Report Third Quarter 2022 Financial Results on November 10, 2022

By Value_Insider Value_Insider • 10-19-2022

IsoPlexis Reports Preliminary First Quarter 2022 Revenue, Streamlines Operating Structure to Support Sustainable Growth

By GuruFocusNews GuruFocusNews • 04-11-2022

ISOPLEXIS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of IsoPlexis Corporation - ISO

By Business Wire Business Wire • 02-14-2023

IsoPlexis Announces the Appointment of former Luminex Corporation Chairman and CEO, Nachum "Homi" Shamir to its Board of Directors

By PurpleRose PurpleRose • 08-23-2022

STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger - AJRD, QUMU, ISO, MAXR

By PRNewswire PRNewswire • 12-31-2022

IsoPlexis to Participate in Upcoming Investor Conferences

By Value_Insider Value_Insider • 11-09-2022